Dual TCR-Expressing T Cells in Cancer: How Single-Cell Technologies Enable New Investigation

Elizabeth M. Muhowski, Laura M. Rogers

Research output: Contribution to journalArticlepeer-review

Abstract

TCR diversity measures are often used to understand the immune response in cancer. Traditional measures of diversity rely on bulk RNA sequencing (RNAseq) of the β-chain variable regions. However, the full αβ TCR repertoire is a combination of both the α- and β-chains, which are encoded by separate genes. In contrast with bulk RNAseq, single-cell RNAseq (scRNAseq) allows paired chain analyses, yielding a more accurate measure of the repertoire. Interestingly, ~30% of mature peripheral T cells express multiple TCR alleles (e.g., two α-chains) and may exhibit dual Ag specificity. scRNAseq has become increasingly common, and data from both human and animal studies are publicly available. However, routine workflows discard secondary TCR alleles and focus on a single TCR clone per cell. This perspectives piece emphasizes why this may not be good practice and highlights unanswered questions in the field of T cell dual specificity.

Original languageEnglish (US)
Pages (from-to)299-306
Number of pages8
JournalImmunoHorizons
Volume7
Issue number5
DOIs
StatePublished - May 2023

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'Dual TCR-Expressing T Cells in Cancer: How Single-Cell Technologies Enable New Investigation'. Together they form a unique fingerprint.

Cite this